We’re developing a pipeline of innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. Our lead program, REN-001, is being developed for BAG3-associated dilated cardiomyopathy (DCM) and uses gene transfer technology to address the monogenic cause of this severe form of heart failure.

In July, SOTIO Biotech launched an aggressive phase 2 basket trial of its lead candidate, the IL-15-targeting SOT101, as monotherapy and in combination with pembrolizumab (Keytruda) in patients with selected relapsed/refractory advanced/metastatic solid tumors.

Etkin explains that in the cerebral cortex—the outermost layer of the brain—are systems responsible for a number of higher functions, including cognitive functions like planning,

Ashvattha Therapeutics today announced that the first patient has been enrolled in a two-stage Phase 2 clinical study of D-4517.2, an HDT with potent anti-VEGF activity.

Unlike many CFOs who tell us that their finance career paths did not intersect with the investor relations (IR) function until shortly before their arrival in the CFO office, Chuck Triano relates that his actually began inside the IR function.

As CEO of Portage Biotech, a clinical-stage company, Walters and his team are following a potentially disruptive scientific path to advance first-in-class immunotherapies that elevate or initiate the immune response across a range of cancer types.

Kathy Lee-Sepsick, the founder of Femasys, is determined to change the game in long-neglected areas of women’s healthcare, some of which haven’t had much innovation in more than a century.

A Navy veteran, former marathon runner, and father from Florida is riding to raise money for a deadly condition. He founded the group 20 years ago after his 23 year old daughter tragically died from sepsis. Carl Flatley traveled more than 200 miles and raised $35,000 last year. This year he has bigger goals.